Physician profile
Peta Gay Bezek
NPI 1396281911
$2,077.31
in general payments reported to CMS, 2019-2025
13 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $203 · 2023: $66.76 · 2024: $161 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,110 · Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,110.00 |
| Food and Beverage | $585.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,126.87 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $201.99 | 2022-2025 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $158.57 | 2021-2022 | |
| Axsome Therapeutics, INC. | $136.15 | 2022-2025 | Auvelity |
| Abbvie INC. | $134.94 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $87.69 | 2022-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $56.10 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $56.06 | 2024-2025 | Hetlioz, Fanapt |
| Amgen INC. | $41.07 | 2024 | Otezla, Repatha |
| Alkermes, INC. | $28.19 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.34 | 2021 | |
| Lundbeck LLC | $16.85 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peta Gay Bezek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.